Plexium Announces Appointment of Michael Martin, Ph.D. as President and CEO
SAN DIEGO, Jan. 16, 2024 /PRNewswire/ -- Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Michael Martin, Ph.D. as President and Chief Executive Officer, and a member of the Board of Directors.
- SAN DIEGO, Jan. 16, 2024 /PRNewswire/ -- Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Michael Martin, Ph.D. as President and Chief Executive Officer, and a member of the Board of Directors.
- "I look forward to working with Mike to advance our clinical-stage pipeline and progressing more TPD programs against important cancer targets into the clinic."
- I am excited to lead Plexium and continue to build a leading TPD company focused on improving patients' lives."
- Dr. Martin joined Takeda in 2012 and prior to his most recent role, he was President of Takeda Ventures, Inc., Takeda's corporate venture capital company.